ClinicalTrials.gg
RecruitingNCT05958719Updated Dec 30, 2024

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

A Phase 2 interventional study of Chidamide and Azacitidine in Peripheral T Cell Lymphoma and Epigenetic Repression, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-30.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Mar 2023, registered Jul 2023).
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral — 17 open to participants now, 18 under way, 2 of them phase 3. tucidinostat · Lymphoma, T-Cell, Peripheral.

Planned enrollment
17th of 29
37 · median 44
Started
2023
with 4 others
Phase 2
16 of 29
8 open now
Primary completion
2026-12
later than 7 of 17 live
Registered
19th of 29
by date
Lead sponsor
1 of 29
Institute of Hematology & Blood Diseases Hospital, China

Among the 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral, this one is the 17th largest by planned enrollment, is one of 5 that started in 2023, is one of 16 in phase 2, reaches primary completion later than 7 of the 17 other live ones, and was the 19th registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

17 of the 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral are open now, in 2 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

About tucidinostat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral, or all of them as a file.
02

Study summary

This study is investigating the effectiveness (specifically the objective response rate - ORR) of a new combination therapy called CAMP (chidamide, azacitidine, liposomal mitoxantrone, and prednisone) for previously untreated angioimmunoblastic T-cell lymphoma (AITL). It's a single-arm study comparing CAMP's safety and efficacy to standard treatments. Younger patients (≤70) receive the full CAMP regimen, while older patients receive a modified version (CAMP-light). Patients are assessed via PET-CT after 4 cycles. Responders (CR/PR) receive consolidation therapy and then maintenance chidamide for 2 years. Eligible patients achieving CR after 4 cycles can get a transplant, while those with PR need 2 more cycles first. Patients with stable or progressive disease after 4 cycles are withdrawn. Progression at any time leads to study discontinuation.

Read the detailed description

Main Objective:

The primary objective of this study is to investigate the objective response rate (ORR) of chidamide in combination with azacitidine, liposomal mitoxantrone, and prednisone (CAMP regimen) for the treatment of treatment-naïve angioimmunoblastic T-cell lymphoma (AITL).

Study Design:

This study employs a single-arm design, based on the hypothesis that the safety profile of the chidamide, azacitidine, liposomal mitoxantrone, and prednisone (CAMP regimen) is superior to conventional treatment regimens, and that the efficacy, as measured by ORR, is non-inferior to conventional treatment regimens. Patients meeting the inclusion/exclusion criteria will be treated according to age: patients ≤70 years old will receive the CAMP regimen as first-line therapy, while patients >70 years old will receive a modified CAMP regimen (CAMP-light) as first-line therapy. Interim efficacy will be assessed via PET-CT scan after the 4th cycle of chemotherapy, with PET-CT results interpreted using the Deauville 5-point scale.

Treatment and Follow-up:

Patients achieving a complete response (CR) or partial response (PR) at the interim assessment will continue with 2 cycles of consolidation therapy using the CAMP regimen or CAMP-light regimen. Subsequently, they will enter single-agent chidamide maintenance therapy (≤70 years old: chidamide 30mg orally, twice weekly; >70 years old: chidamide 20mg orally, twice weekly), which will continue for 24 months.

Patients eligible for transplantation who achieve a CR after 4 cycles of induction therapy may proceed to autologous stem cell transplantation (ASCT). Patients achieving a PR will receive 2 additional cycles of consolidation therapy before undergoing ASCT. Patients with a PR at the interim assessment will undergo a repeat PET-CT scan before transplantation to reassess efficacy. Stem cell mobilization for transplant-eligible patients will utilize steady-state mobilization with or without plerixafor.

Patients exhibiting stable disease (SD) or progressive disease (PD) at the interim assessment after 4 cycles will be withdrawn from the study.

Patients experiencing PD at any time during the treatment course will be discontinued from the study upon confirmation of progression.

03

Conditions studied

  • Peripheral T Cell Lymphoma
  • Epigenetic Repression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must have histological confirmation of nodal T-follicular helper (TFH) cell lymphoma.
  2. More than 18 years of age.
  3. Proper functioning of the major organs: 1) The absolute value of neutrophils (≥1×10\^9/L); 2) count (≥75×10\^9/L); 3) Serum total ≤ 1.5 times ; 4) (AST), Alanine Aminotransferase (ALT) ≤3 times ULN; 5) Serum creatinine (Cr) ≤2 ULN, or ≥40ml/min;
  4. (ECOG) Performance status 0-2.
  5. value measured by echocardiography ≥50%.
  6. > 3 months.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have previously received chemotherapy, radiotherapy or other antitumor therapy.
  2. Patients with central nervous system involvement by lymphoma.
  3. Patients with uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, serious infectious diseases and other diseases.
  4. Pregnant or breastfeeding women.
  5. Presence of (HIV) virus infection.
  6. Previous history of other malignant tumors, unless the disease has been cured for 5 years or more. The following cured tumors are excluded:

    1. Basal cell carcinoma of the skin, squamous cell carcinoma of the skin and related localized non-melanoma skin cancers;
    2. Carcinoma in situ of the cervix
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
37 participants (estimated)

Study arms

  • Experimental
    interim evaluation of CR group

    Untreated patients with TFH-derived peripheral T-cell lymphoma will be treated with chidamide, azacitidine, liposomal mitoxantrone, and prednisone (CAMP regimen) for four cycles. For patients with interim-PET evaluation of CR, consolidation therapy with ASCT or another two cycles with CAMP regimen can be obtained. Subsequently,chidamide monotherapy was given as maintenance therapy for 24 months. Patients with interim evaluation of SD or PD withdrew from this study.

    Drug: Chidamide · Drug: Azacitidine · Drug: liposomal mitoxantrone · Drug: prednisone

  • Experimental
    interim evaluation of PR group

    Untreated patients with TFH-derived peripheral T-cell lymphoma will be treated withchidamide, azacitidine, liposomal mitoxantrone, and prednisone (CAMP regimen) for four cycles. For patients with interim-PET evaluation of PR, another two cycles of CAMP regimen will be continued, followed by the second PET-CT efficacy evaluation, and those who achieve CR receive consolidation therapy with ASCT and following chidamide maintenance. Subsequently, chidamide monotherapy was given as maintenance therapy for 24 months. Patients with second efficacy evaluation of PR or SD or PD withdrew from this study.

    Drug: Chidamide · Drug: Azacitidine · Drug: liposomal mitoxantrone · Drug: prednisone

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the incidence of either a CR or a partial response (PR) per the Lugano Classification by PET-CT as determined by study investigators.

    Time frame: 2 years post initiation of treatment

  2. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: 2 years post initiation of treatment

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the time from the initiation of treatment to the date of disease progression or death from any cause.

    Time frame: 2 years post initiation of treatment

  2. Duration of Response (DOR)

    DOR is defined for participants who experience complete response after treatment and is the time from the first objective response to disease progression or death from any cause.

    Time frame: 2 years post initiation of treatment

  3. Overall Survival (OS)

    OS is defined as the time from initiation of treatment to the date of death from any cause.

    Time frame: 2 years post initiation of treatment

Other outcomes

  1. levels of lymphocyte subsets in blood

    Time frame: 2 years post initiation of treatment

  2. levels of cytokines in serum

    Cytokines assessed by flow cytometry: including IL-10, IL-6, IL-8, IFN-α, IFN-γ, and TNF-α.

    Time frame: 2 years post initiation of treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.

Of 44 non-industry phase 2 interventional studies under Lymphoma, T-Cell, Peripheral, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 110. This study's planned 45 months is below that.

Counting every sponsor, half of 64 studies reached it within 61 months; a quarter within 38 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2023
First posted
Jul 25, 2023
StartActual
Mar 2, 2023
Primary completionEst.
Dec 30, 2026
CompletionEst.
Mar 2, 2027
Last update
Dec 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05958719
Responsible party
Zou Dehui (Assistant Director of lymphoma Diagnosis and Treatment Center, Institute of Hematology & Blood Diseases Hospital, China) — Principal investigator
First posted
Jul 25, 2023
Start date
Mar 2, 2023
Primary completion
Dec 30, 2026 (estimated)
Completion
Mar 2, 2027 (estimated)
Last update
Dec 30, 2024

Study contacts

Dehui Zou, Dr.
Contact
zoudehui@ihcams.ac.cn
86-022-23909282
Huimin Liu, Dr.
Contact
liuhuimin@ihcams.ac.cn
86-022-23909282
Dehui Zou, Dr.
principal investigator · Institute of Hematology & Blood Diseases Hospital, China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tucidinostat · Azacitidine · Mitoxantrone · Prednisone

Start the discussion